|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen Z, Fillmore CM, Hammerman PS, Kim CF
and Wong KK: Non-small-cell lung cancers: A heterogeneous set of
diseases. Nat Rev Cancer. 14:535–546. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sharma SV, Bell DW, Settleman J and Haber
DA: Epidermal growth factor receptor mutations in lung cancer. Nat
Rev Cancer. 7:169–181. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huang Y and Carbone DP: Mechanisms of and
strategies for overcoming resistance to anti-vascular endothelial
growth factor therapy in non-small cell lung cancer. Biochim
Biophys Acta. 1855:193–201. 2015.PubMed/NCBI
|
|
5
|
Carmeliet P and Jain RK: Principles and
mechanisms of vessel normalization for cancer and other angiogenic
diseases. Nat Rev Drug Discov. 10:417–427. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ellis LM and Hicklin DJ: VEGF-targeted
therapy: Mechanisms of anti-tumour activity. Nat Rev Cancer.
8:579–591. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cha JY, Kim YT, Kim HS and Cho YS:
Antihyperglycemic effect of stem bark powder from paper mulberry
(Broussonetia kazinoki Sieb.) in type 2 diabetic Otsuka Long-Evans
Tokushima fatty rats. J Med Food. 11:499–505. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bae UJ, Jang HY, Lim JM, Hua L, Ryu JH and
Park BH: Polyphenols isolated from Broussonetia kazinoki prevent
cytokine-induced β-cell damage and the development of type 1
diabetes. Exp Mol Med. 47:e1602015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee JK, Ha H, Lee HY, Park SJ, Jeong SL,
Choi YJ and Shin HK: Inhibitory effects of heartwood extracts of
Broussonetia kazinoki Sieb on the development of atopic dermatitis
in NC/Nga mice. Biosci Biotechnol Biochem. 74:1802–1806. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ryu JH, Ahn H and Jin Lee H: Inhibition of
nitric oxide production on LPS-activated macrophages by kazinol B
from Broussonetia kazinoki. Fitoterapia. 74:350–354. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim HS, Lim J, Lee DY, Ryu JH and Lim JS:
Kazinol C from Broussonetia kazinoki activates AMP-activated
protein kinase to induce antitumorigenic effects in HT-29 colon
cancer cells. Oncol Rep. 33:223–229. 2015.PubMed/NCBI
|
|
12
|
Jung YC, Han S, Hua L, Ahn YH, Cho H, Lee
CJ, Lee H, Cho YY, Ryu JH, Jeon R, et al: Kazinol-E is a specific
inhibitor of ERK that suppresses the enrichment of a breast cancer
stem-like cell population. Biochem Biophys Res Commun. 470:294–299.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cho YR, Kim JH, Kim JK, Ahn EK, Ko HJ, In
JK, Lee SJ, Bae GU, Kim YK, Oh JS, et al: Broussonetia kazinoki
modulates the expression of VEGFR-2 and MMP-2 through the
inhibition of ERK, Akt and p70S6K-dependent signaling
pathways: Its implication in endothelial cell proliferation,
migration and tubular formation. Oncol Rep. 32:1531–1536.
2014.PubMed/NCBI
|
|
14
|
Kim JH, Kim JK, Ahn EK, Ko HJ, Cho YR, Lee
CH, Kim YK, Bae GU, Oh JS and Seo DW: Marmesin is a novel
angiogenesis inhibitor: Regulatory effect and molecular mechanism
on endothelial cell fate and angiogenesis. Cancer Lett.
369:323–330. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen IS, Chang CT, Sheen WS, Teng CM, Tsai
IL, Duh CY and Ko FN: Coumarins and antiplatelet aggregation
constituents from formosan Peucedanum japonicum. Phytochemistry.
41:525–530. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim JS, Kim JC, Shim SH, Lee EJ, Jin W,
Bae K, Son KH, Kim HP, Kang SS and Chang HW: Chemical constituents
of the root of Dystaenia takeshimana and their anti-inflammatory
activity. Arch Pharm Res. 29:617–623. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jain M, Kapadia R, Jadeja RN, Thounaojam
MC, Devkar RV and Mishra SH: Hepatoprotective activity of Feronia
limonia root. J Pharm Pharmacol. 64:888–896. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Znati M, Ben Jannet H, Cazaux S, Souchard
JP, Skhiri F Harzallah and Bouajila J: Antioxidant, 5-lipoxygenase
inhibitory and cytotoxic activities of compounds isolated from the
Ferula lutea flowers. Molecules. 19:16959–16975. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
In JK, Kim JK, Oh JS and Seo DW:
5-Caffeoylquinic acid inhibits invasion of non-small cell lung
cancer cells through the inactivation of p70S6K and Akt
activity: Involvement of p53 in differential regulation of
signaling pathways. Int J Oncol. 48:1907–1912. 2016.PubMed/NCBI
|
|
20
|
Yoon HJ, Cho YR, Joo JH and Seo DW:
Knockdown of integrin α3β1 expression induces proliferation and
migration of non-small cell lung cancer cells. Oncol Rep.
29:662–668. 2013.PubMed/NCBI
|
|
21
|
Lee HN, Joo JH, Oh JS, Choi SW and Seo DW:
Regulatory effects of Siegesbeckia glabrescens on non-small cell
lung cancer cell proliferation and invasion. Am J Chin Med.
42:453–463. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Joo JH, Hong SS, Cho YR and Seo DW:
10-Gingerol inhibits proliferation and invasion of MDA-MB-231
breast cancer cells through suppression of Akt and
p38MAPK activity. Oncol Rep. 35:779–784. 2016.PubMed/NCBI
|
|
23
|
Bourboulia D and Stetler-Stevenson WG:
Matrix metalloproteinases (MMPs) and tissue inhibitors of
metalloproteinases (TIMPs): Positive and negative regulators in
tumor cell adhesion. Semin Cancer Biol. 20:161–168. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: Regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Overall CM and Kleifeld O: Tumour
microenvironment - opinion: Validating matrix metalloproteinases as
drug targets and anti-targets for cancer therapy. Nat Rev Cancer.
6:227–239. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vandenbroucke RE and Libert C: Is there
new hope for therapeutic matrix metalloproteinase inhibition? Nat
Rev Drug Discov. 13:904–927. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Seo DW, Li H, Guedez L, Wingfield PT, Diaz
T, Salloum R, Wei BY and Stetler-Stevenson WG: TIMP-2 mediated
inhibition of angiogenesis: An MMP-independent mechanism. Cell.
114:171–180. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stetler-Stevenson WG: Tissue inhibitors of
metalloproteinases in cell signaling: Metalloproteinase-independent
biological activities. Sci Signal. 1:re62008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kim HJ, Cho YR, Kim SH and Seo DW:
TIMP-2-derived 18-mer peptide inhibits endothelial cell
proliferation and migration through cAMP/PKA-dependent mechanism.
Cancer Lett. 343:210–216. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lemmon MA and Schlessinger J: Cell
signaling by receptor tyrosine kinases. Cell. 141:1117–1134. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Desgrosellier JS and Cheresh DA: Integrins
in cancer: Biological implications and therapeutic opportunities.
Nat Rev Cancer. 10:9–22. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee HN, Kim JK, Kim JH, Lee SJ, Ahn EK, Oh
JS and Seo DW: A mechanistic study on the anti-cancer activity of
ethyl caffeate in human ovarian cancer SKOV-3 cells. Chem Biol
Interact. 219:151–158. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim SH, Cho YR, Kim HJ, Oh JS, Ahn EK, Ko
HJ, Hwang BJ, Lee SJ, Cho Y, Kim YK, et al: Antagonism of
VEGF-A-induced increase in vascular permeability by an integrin
α3β1-Shp-1-cAMP/PKA pathway. Blood. 120:4892–4902. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Claesson-Welsh L and Welsh M: VEGFA and
tumour angiogenesis. J Intern Med. 273:114–127. 2013. View Article : Google Scholar : PubMed/NCBI
|
